<DOC>
	<DOC>NCT03017014</DOC>
	<brief_summary>The primary objective of this study is to evaluate long-term effectiveness of adalimumab in pediatric participants starting a treatment for Crohn's disease in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach. Main secondary objectives are to describe growth and pubertal development and to describe long-term safety. The participants will be followed-up up to 10 years.</brief_summary>
	<brief_title>A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>With confirmed diagnosis of Crohn's disease Adalimumabnaïve patient (a patient having received an antiTNF other than adalimumab may enter the study) Starting a treatment with adalimumab Guardian capable of and willing to grant authorization for use/disclosure of data collected and patient able to comply with the requirements of the study protocol. Participants with a history of treatment with adalimumab Participants enrolled in a concomitant interventional clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Humira®</keyword>
	<keyword>Adalimumab</keyword>
</DOC>